Table 2:
Strategies by modulating NAD-consuming enzymes.
| Targets | Compounds | Disease model | Effects | Ref. |
|---|---|---|---|---|
| Sirtuin activity modulators | ||||
| SIRT1 activator | Resveratrol | Cerebral ischemia (CI) | SIRT1 activation modulates neuronal survival in aged CI mice in an Akt-dependent manner | [154] |
| SIRT1 activator | Sulfonamide derivatives | 6-OHDA-treated neuronal cell | SIRT1 activation by sulfonamide derivatives can protect SH-SY5Y from 6-OHDA-induced cell death | [155] |
| SIRT1 activator | NeuroHeal | Peripheral nerve axotomy | NeuroHeal can activate the pro-survival autophagy process and protect pups from peripheral nerve axotomy by the concomitant activation of SIRT1 and the PI3K/Akt pathway | [156] |
| SIRT2 inhibitor | AGK2 | Ischemic stroke model | SIRT2 inhibitor AGK2 or sirt2 knockout have neuroprotective effects in the transient middle cerebral artery occlusion mouse model | [157] |
| SIRT2 inhibitor | Thioamide 53 | Thioamide 53 can promote neurite outgrowth of Neuro-2a cells | [158] | |
| PARP inhibitors | ||||
| Olaparib | Schinzel-Giedion syndrome (SGS) | The neurodegeneration caused by inheritable DNA damage can be alleviated by PARP1 inhibition | [62] | |
| 10e | PD | 10e protects neurons from α-synuclein pre-formed fiber-mediated neurotoxicity and helps maintain normal NAD levels | [159] | |
| PJ34 | Rat forebrain ischemia | PJ34 almost completely inhibits neuroinflammation and reduces CA1 neuronal death by 84%. | [160] | |
| PJ34 | Rotenone-treated Drosophila | PARP1 inhibition by PJ34 reduces dSARM expression, and protects Drosophila from rotenone-induced loss of locomotor ability. | [161] | |
| INO1001 | Aortic cross-clamping-induced ischemia/reperfusion | INO1001 markedly protects the spinal cord from aortic occlusion-induced injury. | [162] | |
| INO1001 | Brain traumatic injury | INO1001 significantly reduces microglial activation and increases neuronal survival after TBI. | [163] | |
| INO1001 | R6/2 mutant Huntington’s disease mouse model | INO1001 prolongs R6/2 mutant mouse survival, and reduces severe signs of neurological dysfunction compared to vehicle control | [164] | |
| SARM1 inhibitors | ||||
| Berberine Chloride | Chronic acrylamide-induced axon destruction | Berberine treatment significantly ameliorates axonal degeneration, alleviates pathological changes in the sciatic nerve and spinal cord, and improves neurobehavioral symptoms in acrylamide-treated rats. | [165] | |
| DSRM-3716 | Rotenone-induced axon degeneration | SARM1 inhibition by DSRM-3716 rescues rotenone-treated axons that are fated to degenerate | [166] | |
| NB-3 |
Nerve injury model Vincristine-induced neuropathy model |
NB-3 is covalently conjugated with SARM1 product ADPR and exerts a potent protective effect against nerve injury | [167] | |
| EV-99 | Vacor and vincristine-induced neuropathy | EV-99 covalently binds to C311 of SARM1, and protects axons from vincristine- and vacor-induced neurite degeneration in cultured dorsal root ganglion neurons | [168] | |
| CD38 inhibitors | ||||
| 78c | age | 78c can reverse age-related NAD decline, and improve age-related physiological and metabolic parameters | [169] | |
| 78c | age | Increases lifespan and health span of naturally aged mice | [170] | |
| apigenin | Diabetes, cell senescence, neuroinflammation | Apigenin has protective effects in age-related diabetes, age-related cell senescence, and LPS-induced neuroinflammation and cognitive impairment | [89, 171–173] | |
| MK-0159 | Ischemia/reperfusion | MK-0159 shows strong protection against I/R-induced myocardial damage | [174] | |
| Other enzymes | ||||
| Phosphodiesterase (PDE)10A | papaverine | Quinolinic acid-treated primary cortical neuron | Papaverine can increase cellular NAD levels, restore mitochondrial membrane potential, reduce ROS levels, and show neuroprotective activity | [175] |
| PDE4 | Roflumilast | Quinolinic acid-treated primary cortical neuron | Roflumilast can increase intracellular NAD content and protects primary cortical neurons from quinolinic acid-induced toxicity | [176] |
| PED4 | Roflupram | MPP(+)-treated neuronal cells | Roflupram protects dopaminergic neurons from MPP(+)-induced apoptotic cell death via CREB/PGC1α pathways | [177] |
| Roflupram | Rotenone-treated SH-SY5Y cells | Roflupram can increase the NAD/NADH levels, activate lysosome function, and reduce α-syn levels in rotenone-treated neuronal cells. | [178] |